Oncology News | pharmaphorum

News

ASCO: Conversational AI tackles missed colonoscopies

An artificial intelligence-based tool has shown impressive results in raising colorectal cancer screening rates in underserved populations.

News

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

News

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.

News

First patient gets bowel cancer jab in NHS 'matchmaker' push

The first patient has received a personalised colorectal cancer vaccine, produced by BioNTech, as part of NHS England and Genomics England’s Cancer Vaccine Launch Pad (CVL

ASCO: Conversational AI tackles missed colonoscopies

ASCO: Gilead sifts lung cancer data for efficacy crumbs

ASCO: Novartis’ Scemblix aces first-line CML study

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Gilead’s Trodelvy woes rise with failed bladder cancer trial

First patient gets bowel cancer jab in NHS 'matchmaker' push

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks